Skip to main content

Table 5 Application of the proposed and comparison methods to the determination of ALD in tablet dosage forms

From: Validated spectrophotometric methods for determination of Alendronate sodium in tablets through nucleophilic aromatic substitution reactions

Pharmaceutical preparation Method I Method II Method III   Comparison method (7)
  Conc. taken (μg/mL) % Found Conc. taken (μg/mL) % Found Conc. taken (μg/mL) % Found  
Osteonate ® tablets 10.00 99.24 16.00 99.92 18.00 98.17 101.16
(13.05 mg
ALD/tablet) a
15.00
20.00
98.41
97.51
20.00
40.00
97.50
99.08
24.00
30.00
97.88
100.70
102.67
99.65
‾ x ± S.D. 98.39 ± 0.87 98.83 ± 1.23 98.92 ± 1.55 101.16 ± 1.51
t 2.756 (2.776)* 2.073 (2.776)* 1.792 (2.776)*  
F 3.012 (19.00)* 1.507 (19.00)* 1.064 (19.00)*  
Alendex ® tablets 10.00 101.67 16.00 100.25 18.00 101.67 97.21
(52.2 mg
ALD/tablet) b
15.00
20.00
98.32
100.34
20.00
40.00
99.83
98.85
24.00
30.00
98.65
99.81
101.00
99.25
‾ x ± S.D. 100.11 ± 1.67 99.64 ± 0.72 100.04 ± 1.52 99.15 ± 1.90
t 0.655 (2.776)* 0.409 (2.776)* 0.422 (2.776)*  
F 1.294 (19.00)* 6.964 (19.00)* 1.054 (19.00)*  
  1. Each result is the average of three separate determinations
  2. *Values between brackets are the tabulated t and F values, at p = 0.05 [45]